The Center for Biosimilars’ Post

Key Considerations in Treatment Selection for Patients With Multiple Myeloma: Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed. #finance #pharmacy #lifesciences

Your Weekly Dose of Biosimilar News:💉 * Dr. Niazi is here to break down interchangeability like Thanos explaining the Infinity Stones * Tyenne's the new tocilizumab biosimilar on the block, but don't worry, it's been approved by the FDA * Alvotech's got another biosimilar approved, making them a biosimilar boss like Beyonce * Julie Reed is giving us a biosimilar industry forecast - get ready for major policy shifts and hopefully more people switching to biosimilars * The AON is saving major $$ with biosimilars - that's more money for epic patient care https://lnkd.in/e_KR7hhk

We're seeking individuals to participate in a clinical study to prevent serious cardiovascular events using Inclisiran 🩺. Sponsored by Novartis Pharmaceuticals, this study targets those at high risk but who have not had a cardiovascular event ❤️. For those interested or seeking more details, contact our study team. Your participation could contribute to breakthroughs in cardiovascular disease prevention. Visit the link for more information: https://lnkd.in/gAbC4Aqs 🩺 Medcare Pharma: Your Way to Cure Contact us: ☎️ | 1-866-4-MEDICINE 📧 | info@medcarepharma.care 🌐 | https://lnkd.in/gA9pPUVR #cardiovascular #diseaseprevention #clinicaltrial #clinicalresearch #medicalresearch #clinicalstudies #clinicalstudy #healthcare #medcarepharma #researchstudies

Join our BootCamp and dive into comprehensive sessions on Rheumatology, including DMARDs, Biologics, and living with Inflammatory Arthritis. Learn beyond the basics of Rheumatoid Arthritis and equip yourself with essential knowledge. Don't miss out – register today! https://lnkd.in/esC7TjiH #Rheumatology #BootCamp #InflammatoryArthritis #GrandRapids #MedicalEducation

Join our BootCamp and dive into comprehensive sessions on Rheumatology, including DMARDs, Biologics, and living with Inflammatory Arthritis. Learn beyond the basics of Rheumatoid Arthritis and equip yourself with essential knowledge. Don't miss out – register today! https://lnkd.in/esC7TjiH #Rheumatology #BootCamp #InflammatoryArthritis #GrandRapids #MedicalEducation

After 19 long years and close to 20 clinical trials, Verona Pharma has received FDA approval for #OHTUVAYRE (ensifentrine). Ohtuvayre, a selective dual inhibitor targeting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, uniquely merges two therapeutic actions in one medication. This novel treatment both dilates the airways and mitigates inflammation in COPD patients. Representing the first significant therapeutic advancement in over a decade, it addresses the chronic inflammation and airflow restriction characteristic of COPD, providing much-needed relief to patients struggling to breathe. Find the clinical evidence for Ohtuvayre (ensifentrine) @ DRUGDOCS® https://lnkd.in/ey5iiWiP

Topline data from Phase I trial of Arecor Therapeutics plc's ultra-rapid ultra-concentrated #insulin AT278 in Type II #diabetes has shown superiority to benchmark fast-acting or concentrated insulins. AT278's unique profile could address diabetic patients with high insulin needs & is suited for the emerging needs of next-gen insulin pumps. For more on #AREC: https://lnkd.in/dKSWwywj

Irritable Bowel Syndrome Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | 4D Pharma, OrphoMed, Takeda, CinRx, Rottapharm, Biomica, Metacrine, Serentrix, Renexxion #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

𝐈𝐨𝐧𝐢𝐬 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐎𝐥𝐞𝐳𝐚𝐫𝐬𝐞𝐧 𝐢𝐧 𝐅𝐂𝐒 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) Ionis Pharmaceuticals, Inc. announces Phase 3 Balance study results of olezarsen for familial chylomicronemia syndrome (FCS) treatment. The olezarsen 80 mg monthly dose significantly reduced triglycerides (TGs) in genetically validated FCS patients at six months. Robust TG and apoC-III reductions were sustained, with fewer acute pancreatitis (AP) events versus placebo over 12 months. Olezarsen demonstrated favorable safety and tolerability. These findings, presented at the 2024 ACC Annual Meeting and published in NEJM, support regulatory approval. #Olezarsen #FCS #ClinicalTrialResults #Healthcare #MedicalResearch #Cardiology #ACCAnnualMeeting #NEJM #RegulatoryApproval